Virax Biolabs Group Ltd (VRAX) — 6-K Filings

6-K Filings (23)

• Virax Biolabs Files 6-K Report — Apr 14, 2026 Risk: low
  Virax Biolabs Group Ltd filed a 6-K report on April 14, 2026, detailing its operations and business address at BIOCITY GLASGOW, BO'NESS ROAD, NEWHOUSE LANARKSHI
• 6-K Filing — Dec 4, 2025
• 6-K Filing — Dec 2, 2025
• Virax Biolabs Director Ian Martin Departs Board — Jul 30, 2025 Risk: low
  Virax Biolabs Group Ltd. announced the departure of Ian Martin from its Board of Directors, effective July 29, 2025. Martin had served as a director since Septe
• Virax Biolabs CFO Resigns — Jun 13, 2025 Risk: medium
  Virax Biolabs Group Ltd announced on June 13, 2025, the resignation of Jason Davis as Chief Financial Officer and Secretary. The company has not yet appointed a
• Virax Biolabs Starts Alzheimer's Diagnostic Test Study — Mar 18, 2025 Risk: medium
  Virax Biolabs Group Ltd. announced on March 18, 2025, that it has initiated a clinical study for its novel diagnostic test for Alzheimer's disease. The study ai
• Virax Biolabs Files 6-K Report — Mar 13, 2025 Risk: low
  Virax Biolabs Group Ltd. filed a Form 6-K on March 13, 2025, to report information for the month of March 2025. The filing indicates the company's principal exe
• Virax Biolabs Files March 2025 6-K Report — Mar 5, 2025 Risk: low
  Virax Biolabs Group Ltd. filed a Form 6-K on March 5, 2025, to report information for the month of March 2025. The filing indicates the company is a foreign pri
• Virax Biolabs Files 6-K for February 2025 — Feb 25, 2025 Risk: low
  Virax Biolabs Group Ltd filed a Form 6-K on February 25, 2025, reporting information for the month of February 2025. The company, previously known as Virax Biol
• Virax Biolabs Reports AGM Results — Dec 23, 2024 Risk: low
  Virax Biolabs Group Ltd filed a Form 6-K on December 23, 2024, reporting results from its Annual General Meeting (AGM) held in December 2024. The filing indicat
• Virax Biolabs Files Form 6-K with SEC — Dec 17, 2024 Risk: low
  On December 17, 2024, Virax Biolabs Group Ltd. filed a Form 6-K, which is a report of foreign private issuers. This filing does not contain specific financial d
• Virax Biolabs Files Form 6-K with SEC — Dec 10, 2024 Risk: low
  On December 10, 2024, Virax Biolabs Group Limited filed a Form 6-K. The filing indicates that the company is a foreign private issuer and is providing informati
• Virax Biolabs Files 6-K for FY25 Q2 Results — Nov 20, 2024 Risk: low
  Virax Biolabs Group Ltd filed a Form 6-K on November 20, 2024, reporting its financial results for the fiscal year ending March 31, 2025, and the second quarter
• Virax Biolabs Files October 2024 6-K Report — Oct 31, 2024 Risk: low
  Virax Biolabs Group Ltd, a foreign private issuer, filed a Form 6-K on October 31, 2024. This report is for the month of October 2024 and indicates the company
• Virax Biolabs Files October 2024 6-K Report — Oct 23, 2024 Risk: low
  On October 23, 2024, Virax Biolabs Group Ltd. filed a Form 6-K with the SEC. This report is for the month of October 2024 and indicates that the company files a
• Virax Biolabs Files September 2024 6-K Report — Sep 30, 2024 Risk: low
  Virax Biolabs Group Ltd. filed a Form 6-K on September 30, 2024, reporting for the month of September 2024. The company, previously known as Virax Biolabs (Caym
• Virax Biolabs Raises $1.5M in Direct Offering — Aug 23, 2024 Risk: medium
  Virax Biolabs Group Ltd. announced a registered direct offering on August 21, 2024, to raise gross proceeds of approximately $1.5 million before deducting under
• Virax Biolabs Director Departs — Jun 11, 2024 Risk: low
  Virax Biolabs Group Ltd. announced the departure of Nigel James, a director, effective June 11, 2024. The company, which is incorporated in the United Kingdom a
• Virax Biolabs Launches Monkeypox Antibody Test Kit — Apr 25, 2024 Risk: medium
  On April 25, 2024, Virax Biolabs Group Ltd. announced the launch of its new diagnostic product, the Virax IgM/IgG Antibody Test Kit for Monkeypox (Mpox). This k
• Virax Biolabs Files 6-K with SEC — Apr 16, 2024 Risk: low
  Virax Biolabs Group Ltd. filed a Form 6-K on April 16, 2024, to report information as a foreign private issuer. The filing provides details about the company's
• Virax Biolabs Files 6-K for Reporting Compliance — Mar 15, 2024 Risk: low
  Virax Biolabs Group Ltd. filed a Form 6-K on March 15, 2024, to report information relevant to its status as a foreign private issuer. The filing indicates the
• Virax Biolabs to Sell Up to $1.45M in Shares via ATM Offering — Jan 22, 2024
  On January 22, 2024, Virax Biolabs Group Limited entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to potentially sell up t
• Virax Biolabs Files Unaudited Q3 2023 Financials — Jan 12, 2024
  Virax Biolabs Group Limited filed a 6-K on January 12, 2024, to announce the release of its unaudited interim financial statements as of September 30, 2023. Thi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX